Innovative Biomarkers
Innovation is at the core of our mission.
QUALIblood is dedicated to pushing the boundaries of scientific advancement in the healthcare industry.
We understand the critical role that biomarkers play in assessing the impact of health interventions.
That’s why we are constantly working on the development of new biomarkers
in line with our commitment to delivering the best and most performant solutions in the field.
We believe that innovation is the key to unlocking the full potential of healthcare.
By consistently pushing boundaries, we aim to empower our clients with the tools they need to make informed decisions about product efficacy and safety.
Our newly available biomarker to predict and prevent the risk of venous trhomboembolism asspciated with the pill.
This simple blood test has been developped by QUALIblood and is available for all customers who want to evaluate the risk of thromboembolism associated with the drug under development. This test is also available to all prescribers (gynecologist, generalist,..) to guide them in the drug selection based on their patient profile.
Want to know more about nAPCsr?
Other indications and conditions are currently under investigation.
Contact us if you want to join one of our clinical studies.
FibWave is a new coagulation test based on the analysis of clot formation kinetics.
FibWave enables the overall coagulation process to be assessed by measuring the changes in turbidity created during the clot formation process.
The qualitative examination and quantitative parameters provided by the clot waveform give information about the overall coagulation process. This test assesses the fibrin generation time.
